Medical AI company Lunit (CEO Seo Beom-seok) announced on the 31st that it has been selected for the '2025 Strategic Technology-Type International Joint Technology Development Project (Global Technology Introduction Type)' hosted by the Korea Institute for Advancement of Technology (KIAT) under the Ministry of Trade, Industry and Energy, and will begin developing an 'AI-based personalized breast cancer full-cycle integrated management platform.'
This project aims to strengthen domestic technological competitiveness and expand overseas market penetration by introducing and further developing excellent overseas technologies. Lunit will receive a total of KRW 3 billion in R&D funding and carry out the project for three years, ending in June 2028.
Lunit's platform will enhance personalized breast density, breast cancer risk, and prognosis assessments, integrating AI technology to provide a comprehensive breast cancer management solution. Specifically, Lunit plans to leverage its subsidiary Volpara Health's "Volpara Scorecard" and "Volpara Density" technologies to further enhance the platform. Lunit plans to expand its AI interpretation technology beyond image analysis to encompass risk prediction and follow-up management. This will create an integrated management system encompassing diagnosis, prediction, treatment planning, prognosis management, and follow-up screening.
This selection is seen as a tangible result of the technological and business synergies anticipated by Lunit through its acquisition of Volpara. The new platform is expected to increase efficiency through automation of the screening process and enable strategic screening design, including early intervention for high-risk groups and prevention of over-testing for low-risk groups.
After completing development, Runit plans to strengthen its leading position in the global breast cancer screening market by obtaining US FDA approval and European CE certification, and plans to expand sales to major markets such as North America and Europe.
Seo Beom-seok, CEO of Lunit, said, “This project selection is the result of the government’s recognition of Lunit’s AI technology and global strategy,” and added, “By combining the breast cancer management technology and AI capabilities acquired through the acquisition of Volpara, we will develop next-generation solutions that provide practical help to both medical professionals and patients.”
- See more related articles
You must be logged in to post a comment.